Arecor Therapeutics PLC (AIM:AREC) (Arecor Therapeutics PLC (AIM:AREC)) will host a webinar led by CEO Sarah Howell and Professor Thomas Pieber discussing results from the company's phase I clinical trial results for AT278, an ultra-concentrated, ultra-rapid-acting insulin. The trial showed AT278 met all primary and secondary endpoints and demonstrated superiority to NovoRapid and Humulin R U-500 in Type 2 diabetics with high BMI. AT278 (500 U/mL) is designed to accelerate insulin absorption at high concentrations.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com